GT Biopharma (GTBP) Debt by Year
GT Biopharma Inc. held $6.8M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters GT Biopharma Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
GTBP Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | $0-100.0% | $714K+12.6% | $634K+553.6% | $97Kn/m | $0 | N/A |
| Cash & Equivalents | $6.8M+72.4% | $4.0M+266.2% | $1.1M-81.0% | $5.7M-36.8% | $9.0M+69.3% | $5.3M+18817.9% | $28K-53.3% | $60K-89.6% | $576K+2931.6% | $19K-59.6% | $47K-94.5% | $855K+1888.4% | $43K-65.0% | $123K+33.7% | $92K |
GTBP Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q/A | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q/A | Q2'2410-Q/A | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $5.0M-5.1% | $8.9M+277.3% | $6.8M+72.4% | $2.5M-60.6% | $5.2M-43.5% | $2.4M+21.3% | $4.0M+266.2% | $6.4M+142.4% | $9.2M+234.3% | $1.9M-4.6% | $1.1M-81.0% | $2.6M+7.4% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More GT Biopharma Inc. financials
Frequently Asked Questions
GT Biopharma Inc. held $6.8M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what GT Biopharma Inc. (GTBP) reported on that line in every period on record.